Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research (EN)

  • Read more about Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research (EN)

Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion

  • Read more about Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion

Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany

  • Read more about Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany

Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures

  • Read more about Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures

Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®

  • Read more about Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®

Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product

  • Read more about Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product

Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris

  • Read more about Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris

Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial

  • Read more about Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial

Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris

  • Read more about Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris

Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

  • Read more about Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions